ArticleOphthalmology and therapy2024

High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab.

Jinsoo Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.